Oppenheimer initiated coverage on Alumis with a new price target
$ALMS
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2025 | $17.00 | Overweight | Wells Fargo |
| 6/10/2025 | $18.00 | Buy | Guggenheim |
| 1/30/2025 | $32.00 | Outperform | Oppenheimer |
| 10/31/2024 | $25.00 | Outperform | Robert W. Baird |
| 10/17/2024 | $30.00 | Buy | H.C. Wainwright |
| 7/23/2024 | Overweight | Cantor Fitzgerald | |
| 7/23/2024 | $29.00 | Outperform | Leerink Partners |
| 7/23/2024 | $32.00 | Buy | Guggenheim |
Wells Fargo initiated coverage of Alumis with a rating of Overweight and set a new price target of $17.00
Guggenheim resumed coverage of Alumis with a rating of Buy and set a new price target of $18.00
Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00
SCHEDULE 13D - ALUMIS INC. (0001847367) (Subject)
SCHEDULE 13D/A - ALUMIS INC. (0001847367) (Subject)
10-Q - ALUMIS INC. (0001847367) (Filer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the quarter ended September 30, 2025, and highlighted recent achievements. "As we continue to advance our pipeline, we are entering an important period for Alumis. Our teams have been working diligently, and we are eagerly anticipating key milestones ahead - with topline Phase 3 ONWARD data for envudeucitinib (envu) in moderate-to-severe plaque psoriasis (PsO) expected to be announced early in the first quarter of 2026, followed by t
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: Guggenheim's 2nd Annual Healthcare Innovation ConferenceNovember 10-12, 2025, Boston, MAFireside chat: Tuesday, November 11, 2025 at 1:30 pm ET Stifel 2025 Healthcare ConferenceNovember 11-13, 2025, New York, NYPresentation: Wednesday, November 12, 2025 at 2:00 pm ET To access the live webcasts please visit the "Events" page of the "Investors" section of the Alumis website. Webcast replays wi
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: Cantor Global Healthcare Conference 2025 in New York, NY on September 3 at 9:45 am ET (fireside chat);Wells Fargo 2025 Healthcare Conference in Boston, MA on September 5 at 9:30 am ET (fireside chat);Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY on September 8 at 4:50 pm ET (fireside chat);H.C. Wainwright 27th Annual Global Investment Conference in New York, NY on Sept
Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi
SC 13D - ALUMIS INC. (0001847367) (Subject)
SC 13G - ALUMIS INC. (0001847367) (Subject)
SC 13D - ALUMIS INC. (0001847367) (Subject)